Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

46,00 0,00 (0,00%) Al cierre: 01:47PM EDT

Recordati Industria Chimica e Farmaceutica S.p.A.

Via Matteo Civitali,1
Milan, MI 20148
Italy
39 02 487871
https://www.recordati.com

Sector(es): Healthcare
Sector: Drug Manufacturers—General
Empleados a tiempo completo: 4300

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Robert Koremans M.D.	CEO & Director	1,93M	N/A	1962
Mr. Luigi Felice La Corte	Group CFO & Exec. Director	1,01M	N/A	1969
Ms. Cathrin Petty	Exec. Director	N/A	N/A	1973
Mr. Giampiero Mazza	Exec. Director	N/A	N/A	1969
Mr. Giorgio De Palma	Exec. Director	N/A	N/A	1974
Ms. Federica De Medici	Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Bibianne Bon	Group Chief Legal Officer	N/A	N/A	N/A
Mr. Gabriele Finzi	Exec. VP of Corp. Devel., Licensing & Innovation	N/A	N/A	N/A
Mr. Giuseppe Gualazzini	Sr. VP of Group HR	N/A	N/A	1959
Mr. Roberto Teruzzi	Exec. VP of Group Industrial Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Gobierno corporativo

El ISS Governance QualityScore de Recordati Industria Chimica e Farmaceutica S.p.A., a día 28 de septiembre de 2023, es 2. Las puntuaciones base son Auditoría: 8; Tablero: 2; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.